Attenuation of Airway and Cardiovascular Responses to Extubation in Chronic Smokers
NCT ID: NCT04659642
Last Updated: 2021-03-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
EARLY_PHASE1
66 participants
INTERVENTIONAL
2020-11-30
2021-03-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Different Doses of Dexmedetomidine on Fentanyl-induced Cough
NCT03126422
Dexmedetomidine Infusion Dose Versus Rapid Bolus Dose Before Tracheal Intubation.
NCT06327399
Dexmedetomidine Versus Ketamine-midazolam Sedation in Awake Fiberoptic Intubation in Suspected Difficult Airway
NCT06946212
Hemodynamic and Cardiac Effects of Dexmedetomidine Versus Fentanyl by Intravenous Infusion as Adjuncts to General Anesthesia in Patients Undergoing Major Abdominal Cancer Surgeries.
NCT07214714
Intratracheal Dexmedetomidine Versus Lidocaine in Eye Surgery
NCT05291221
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The peak changes are noticed about 1 minute following extubation and may continue until 10 minutes . The reflexes ranges from coughing, bucking, agitation to bronchospasm, laryngospasm, laryngeal oedema, negative pressure pulmonary oedema, tachycardia, hypertension, arrhythmias, left ventricular failure, myocardial ischemia, increased bleeding, raised intracranial and intraocular pressure and cerebrovascular hemorrhage in susceptible individuals. Although most patients can tolerate these transient effects without any significant consequences, but this could be detrimental in patients operated for cardiac, neuro or ophthalmic lesions especially if hypertensive or diabetic. However, Tracheal extubation in smokers will increase difficulty.
Smoking is a risk factor for intraoperative and postoperative complications mainly related to pulmonary and cardiovascular systems. Long-term exposure to cigarettes causes an increased response to the mechanical stimulation caused by extubation.
Smoking affects oxygen transport and delivery , Irritants in smoke increase mucous secretion which becomes hyper viscous with impaired tracheobronchial clearance . Smoking increases sympathetic activation due to increased release of catecholamines and the delay in nicotine clearance from the neuroeffector junction leading to higher blood pressure, tachycardia, and increase peripheral vascular resistance .
For a smooth extubation, there should be no straining, movement, coughing, breath holding or laryngospasm. Extubation at light levels of anesthesia or sedation can stimulate reflex responses via tracheal and laryngeal irritation . A variety of drugs such as esmolol, alfentanil, diltiazem, verapamil, fentanyl, and lidocaine have been used to control hemodynamic changes and upper airway tract events, but they all have limitations and side effects.
Alpha2 agonists decrease the sympathetic outflow and noradrenergic activity, thereby counteracting hemodynamic fluctuations occurring at the time of extubation due to increased sympathetic stimulation. Dexmedetomidine, an α2-adrenoreceptor agonist with a distribution half-life of approximately 6 minutes has been successfully used for attenuating the stress response to laryngoscopy .
Single dose of dexmedetomidine before extubation proved to attenuate both airway and hemodynamic reflexes during emergence from anesthesia providing smooth extubation.
The addition of a single dose of dexmedetomidine to a low-dose infusion of remifentanil during emergence from sevoflurane-remifentanil anesthesia was effective in attenuating cough without further respiratory depression after thyroid surgery.
Administered 10 minutes before induction in chronic male smokers, dexmedetomidine was found to suppress increased heart rate and rate-pressure product at 1 and 3 minutes after intubation and, therefore, decrease the need for myocardial oxygen more than fentanyl.
Dexmedetomidine produces sedation while sparing responsiveness to CO2, and thus, it has less effect on respiratory depression. Consequently, it has found utility and regulatory approval for use in bronchoscopic examinations and for weaning intensive care unit patients from mechanical ventilation. In addition, dexmedetomidine has been shown to reduce emergence agitation in children and adults after general anesthesia.
Fentanyl, a synthetic opioid, has been reported to reduce the prevalence of coughing during and after extubation and to suppress the sneezing reflex after abdominal hysterectomy and periocular injections . Fentanyl has also been reported to attenuate the cardiovascular responses to tracheal extubation in elective gynecologic surgery.
The subjects were Adult chronic male smokers, thus representing the population in which secondary response to laryngoscopy and intubation is most common.
The study participants will be divided by mean of randomized complete block design into 3 comparable groups.
Group (A) : (n= 22) will receive Dexmedetomidine 1ug/kg body weight IV diluted to 100ml normal saline (NS) over 15 minutes.
Group (B) : (n=22) will receive Fentanyl 1 ug/kg body weight IV diluted to 100 ml normal saline (NS) over 15 minutes.
Group (C): (n=22) will receive both Dexmedetomidine 1ug/kg body weight mixed with fentanyl 1ug/kg in 100 ml normal saline (NS) over 15 minutes Pre-anesthetic checkup was conducted and a detailed history and complete physical examination recorded. Routine investigations like complete blood picture, blood grouping/typing, blood urea and serum creatinine were done. Patients fulfilling inclusion criteria will be informed about the procedure and its possible complications. Finally, written consent will be taken.
Routine anesthetic technique was used using propofol 2mg/kg, fentanyl 1.5 ug/kg, atracurium 0.5 mg /kg, oxygen and sevoflurane. Standard monitoring with electrocardiography (EKG), pulse oximetry (SpO2), noninvasive BP and End tidal Co2 was done.
About 15 minutes before the estimated time of end of surgery (or at the beginning of closure of skin incision,), inhalation agent (sevoflurane) was cut off and patients in each group received the specified solution intravenously over 15 minutes.
Patients in group A received dexmedetomidine 1 mcg/kg intravenous (IV) in 100 ml normal saline (NS) over 15 minutes ,patients in group B, received Fentanyl 1 mcg/kg (IV) in100 ml NS over 15 minutes, while patients in group C received both Dexmedetomidine 1ug/kg mixed with fentanyl 1ug/kg in 100 ml normal saline (NS) over 15 minutes.
When patients' spontaneous respirations were considered sufficient and patients were able to obey simple commands residual neuromuscular block was antagonized with neostigmine 0.05 mg/kg and atropine 0.02 mg/kg. Oropharyngeal secretions were aspirated before extubation. The endotracheal tube was removed after spontaneous ventilation had returned.
The anesthesiologist performing the extubation was blinded to the study drugs. HR, systolic BP and diastolic BP and oxygen saturation were recorded at the start of bolus drug injection and thereafter at 1, 3, 5, 10 and 15 minutes., Also at the time of extubation and thereafter at 1, 3 and 5 minutes after extubation followed by every 5 minutes for 30 minutes. Duration of anesthesia and surgery are noted.
Data will be analyzed using IBM SPSS advanced statistics (Statistical Package for Social Sciences), version 22 (SPSS Inc., Chicago, IL). Numerical data will be described as median and interquartile range or range or mean and standard deviation as appropriate, while qualitative data were described as number and percentage. Chi-square (Fisher's exact) test was used to examine the relation between qualitative variables as appropriate. Testing for normality was done using Kolmogrov-Smirnov test and Shapiro-Wilk test
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
dexmedetomidine group (group A)
will receive Dexmedetomidine 1ug/kg body weight IV diluted to 100ml normal saline (NS) over 15 minutes.
Dexmedetomidine Injection [Precedex]
the drug is given 15 minutes before the estimated end of surgery
Fentanyl group (group B)
will receive Fentanyl 1 ug/kg body weight IV diluted to 100 ml normal saline (NS) over 15 minutes.
Fentanyl Citrate Injection
the drug is given 15 minutes before the estimated end of surgery
Both Dexmedetomidine and fentanyl group (group C)
will receive both Dexmedetomidine 1ug/kg body weight mixed with fentanyl 1ug/kg in 100 ml normal saline (NS) over 15 minutes.
dexmedetomidine and fentanyl
the combination of the two drugs with the same used doses is given 15 minutes before the estimated end of surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine Injection [Precedex]
the drug is given 15 minutes before the estimated end of surgery
Fentanyl Citrate Injection
the drug is given 15 minutes before the estimated end of surgery
dexmedetomidine and fentanyl
the combination of the two drugs with the same used doses is given 15 minutes before the estimated end of surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* American Society of Anesthesiologists (ASA) II.
* Normotensive and receiving no medications
* Body mass index of 30 kg/m2
* Mallampati classification I-II
Exclusion Criteria
2. Morbid obesity.
3. Current upper respiratory infection
4. Hypovolemia
5. IHD
6. History of sleep apnea or Difficult Intubation.
7. Emergency procedures.
8. Hepatic or renal impairment.
9. Drug allergy to Dexmeditomidine or fentanyl.
20 Years
60 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute, Egypt
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Asmaa Fahmy Mohamed Abdelwahab
Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
naglaa abdullah, prof
Role: PRINCIPAL_INVESTIGATOR
NCI, Cairo university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NCI, Cairo university
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
dexmedetomidine in anesthesia
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.